Inhibitors of DNA-PKcs have been used in vitro in colon cancer models and CLL blasts to enhance sensitivity to radio- and chemo-therapeutic treatments [9, 10], but pediatric malignancies so far have not been studied. Here, PRKDC is linked to colonic neoplasm.